华熙生物：国寿成达减持485万股，持股比例降至5.00%

Group 1 - The main subject of the equity change is Guoshou Chengda (Shanghai) Health Industry Equity Investment Center (Limited Partnership), with major partners including China Life Insurance Co., Ltd. (74.94%), China Life Insurance (Group) Company (16.65%), and China Life Property & Casualty Insurance Co., Ltd. (8.33%) [1] - The equity change involved a reduction from 28,936,504 shares (6.01% of total equity) to 24,083,913 shares (5.00% of total equity), resulting in a decrease of 4,852,591 shares, which is a reduction ratio of 1.0074% [1] - The reduction occurred between November 26, 2025, and January 7, 2026, through concentrated bidding for 2,844,591 shares (0.5906%) and block trading for 2,008,000 shares (0.4169%), with the shares being unrestricted circulating A-shares [1] Group 2 - The disclosed reduction plan has not been fully implemented, with a plan to reduce no more than 2.00% of the total equity by February 23, 2026, and there is a possibility of further reductions in the next 12 months [1]